High-density lipoprotein inhibits the uptake of modified low- density lipoprotein and the expression of CD36 and FcgammaRI. 2010

Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
Laboratório de Imunofisiopatologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil. mdias@usp.br

OBJECTIVE Modified low-density lipoprotein (mLDL), mainly upon oxidative and enzymatic modification, is the major atherogenic lipoprotein. Conversely, high-density lipoprotein (HDL) is considered antiatherogenic because of its ability to remove cholesterol. The aim of this work was to analyze both the influence of HDL on the uptake of mLDL and the expression of CD36 and Fcgamma I receptors on monocytic cell lines during cell differentiation. METHODS Uptake of fluorescein isothiocyanate (FITC)-conjugated LDL and FITC-conjugated mLDL, i.e., copper-oxidized LDL (oxLDL) or trypsin enzyme modified LDL (enzLDL), was analyzed, as well as the expression of CD36 and FcgammaRI in THP-1 and U937 cells, using flow cytometry. RESULTS HDL inhibited the uptake of mLDL, which varied in degree depending on the cell line or type of mLDL. Further, HDL rapidly decreased CD36 and FcgammaRI involved in the uptake of mLDL. CONCLUSIONS We demonstrate that modified LDL promotes specific LDL receptor-independent uptake by monocytic cell lines, and that the uptake of LDL and enzLDL is less than that of oxLDL. In this process, HDL diminishes the uptake of LDL or mLDL, which may involve the down-regulation of receptors (CD36 and Fcgamma I). This regulatory process represents another way by which HDL can be anti-atherogenic and it depends on the type of modification of LDL and the stage of differentiation of monocytes to macrophages.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015151 Immunoblotting Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies. Dot Immunoblotting,Electroimmunoblotting,Immunoelectroblotting,Reverse Immunoblotting,Immunoblotting, Dot,Immunoblotting, Reverse,Dot Immunoblottings,Electroimmunoblottings,Immunoblottings,Immunoblottings, Dot,Immunoblottings, Reverse,Immunoelectroblottings,Reverse Immunoblottings
D017392 Thiobarbituric Acid Reactive Substances Low-molecular-weight end products, probably malondialdehyde, that are formed during the decomposition of lipid peroxidation products. These compounds react with thiobarbituric acid to form a fluorescent red adduct. TBARs
D017452 Receptors, IgG Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor). Antigens, CD16,Antigens, CD32,Antigens, CD64,CD16 Antigens,CD32 Antigens,CD64 Antigen,CD64 Antigens,Fc Gamma Receptor,Fc Receptors, gamma,Fc gamma Receptors,IgG Receptor,IgG Receptors,Leu-11 Antigen,Receptors, Fc gamma,gamma Fc Receptor,gamma Fc Receptors,CD 16 Antigens,CD 32 Antigens,CD 64 Antigens,CDw32 Antigens,Fc gamma RI,Fc gamma RII,Fc gamma RIII,Immunoglobulin G Receptor,Leu-11 Antigens,Antigen, CD64,Antigen, Leu-11,Antigens, CD 16,Antigens, CD 32,Antigens, CD 64,Antigens, CDw32,Antigens, Leu-11,Fc Receptor, gamma,Gamma Receptor, Fc,Leu 11 Antigen,Leu 11 Antigens,Receptor, Fc Gamma,Receptor, IgG,Receptor, Immunoglobulin G,Receptor, gamma Fc,Receptors, gamma Fc,gamma RI, Fc,gamma RII, Fc,gamma RIII, Fc,gamma Receptors, Fc
D051116 Receptors, Scavenger A large group of structurally diverse cell surface receptors that mediate endocytic uptake of modified LIPOPROTEINS. Scavenger receptors are expressed by MYELOID CELLS and some ENDOTHELIAL CELLS, and were originally characterized based on their ability to bind acetylated LOW-DENSITY LIPOPROTEINS. They can also bind a variety of other polyanionic ligand. Certain scavenger receptors can internalize micro-organisms as well as apoptotic cells. Macrophage Scavenger Receptors,Scavenger Receptors,Scavenger Receptors, Macrophage,Acetyl-LDL Receptor,Acetyl-LDL Receptors,Acetylated LDL Receptor,Macrophage Scavenger Receptor,Receptor, Acetyl-LDL,Receptor, Macrophage Scavenger,Scavenger Receptor,Acetyl LDL Receptor,Acetyl LDL Receptors,LDL Receptor, Acetylated,Receptor, Acetyl LDL,Receptor, Acetylated LDL,Receptor, Scavenger,Receptors, Acetyl-LDL
D018110 Receptors, Lipoprotein Cell surface proteins that bind lipoproteins with high affinity. Lipoprotein receptors in the liver and peripheral tissues mediate the regulation of plasma and cellular cholesterol metabolism and concentration. The receptors generally recognize the apolipoproteins of the lipoprotein complex, and binding is often a trigger for endocytosis. Lipoprotein Receptors,Lipoprotein Receptor,Receptors, Lipoproteins,Lipoproteins Receptors,Receptor, Lipoprotein

Related Publications

Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
January 2015, International journal of biological sciences,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
October 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
July 2012, Atherosclerosis,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
December 1990, Angiology,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
May 1990, Biochimica et biophysica acta,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
April 2011, Journal of ethnopharmacology,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
September 2015, The Journal of biological chemistry,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
June 2009, Atherosclerosis,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
June 2022, The Journal of biological chemistry,
Márcia Dias Teixeira Carvalho, and Célia Maria Vieira Vendrame, and Daniel Francisco Jacon Ketelhuth, and Edite Hatsumi Yamashiro-Kanashiro, and Hiro Goto, and Magnus Gidlund
November 2020, Aging,
Copied contents to your clipboard!